| Trial registration number
|
NCT05371288 |
Full text link
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
https://clinicaltrials.gov/show/NCT05371288
|
First author
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
Jeein Kim
|
Contact
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
jeeink2@hs.uci.edu
|
Registration date
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
2022-05-12
|
Recruitment status
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
Not recruiting
|
Study design
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
RCT
|
Allocation
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
Randomized
|
Design
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
Parallel
|
Masking
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
Blind label
|
Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
single-center
|
Study aim
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
Treatment
|
Inclusion criteria
Last imported at : Feb. 8, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
inclusion criteria:
• patients with positive covid testing (ab, rt pcr) and mild-severe symptoms based on covid symptom list
|
Exclusion criteria
Last imported at : Feb. 8, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
• history of a severe sulfa sensitivity (i.e., anaphylaxis, stevens johnson syndrome), allergy to meat products and/or gelatin (alpha gal allergy) and/or a history of an allergic or adverse reaction to nac, alpha lipoic acid and/or gsh.
|
Number of arms
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
2
|
Funding
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
University of California, Irvine
|
Inclusion age min
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
18
|
Inclusion age max
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
100
|
Countries
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
United States
|
Type of patients
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
Mild/moderate disease at enrollment
|
Severity scale
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
2: Mild/moderate disease at enrollment
|
Total sample size
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
50
|
primary outcome
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
Assess Changes in Symptoms of Post-Acute Sequelae of COVID (PASC);Change in Quality of Life Using SF-36 Survey;Change in Time to Clinical Recovery (TTCR);COVID Severity of Symptoms Questionnaire
|
Notes
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
None
|
Phase
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
Phase 1
|
Arms
Last imported at : May 13, 2022, 7 a.m.
Source : ClinicalTrials.gov
|
[{"arm_notes": "", "treatment_id": 2481, "treatment_name": "Alpha lipoic acid+glutathione+n-acetylcysteine", "treatment_type": "Vitamins and dietary supplements+others pharmacological treatment+respiratory agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2482, "treatment_name": "Multivitamin", "treatment_type": "Vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}]
|